Hedging the impact of centralized procurement, Zhongsheng Pharmaceutical has launched 79 new products in the past 5 years

Adhering to innovation and high-quality development has become a winning way for pharmaceutical companies to hedge the impact of centralized procurement

During the reporting period, the Group recorded a revenue of 26.

Innovation has become an important source of power for the strong development of Sino Biopharmaceuticals

Form 50 product groups with over 100 million products

In recent years, the company has achieved a lot in research and development.

In the past three years, the Group has obtained a total of 88 approval documents, and the 33 approval documents in 2021 include varieties approved in the United States and Japan, which means that the company's product quality has reached international standards

Xie Qirun, chairman of the board of directors of Sino Biopharmaceuticals, said at the performance conference on the same day that the company adheres to the strategy of innovation and transformation, and it is expected that 106 new varieties will be approved in the next three years, including 10 innovative drug varieties, many of which are expected to sell more than 1 billion yuan.